This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

ExpertPerspectives: Advances in the Management of Pancreatic Cancer: From Bench to Bedside

ExpertPerspectives: Advances in the Management of Pancreatic Cancer: From Bench to Bedside

Format

Webcast

Time to Complete

1 hour

Released

February 28, 2019

Expires

February 27, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by the Annenberg Center for Health Sciences at Eisenhower

Commercial Supporter

This activity is supported by an independent educational grant from Ipsen Biopharmaceuticals and Celgene Corporation.

Program Description

Eileen M. O’Reilly, MD, reviews the molecular pathogenesis and genetics of pancreatic cancer, and outcomes for different subsets of patients; talks about identifying patients who should be referred for management to a high-volume treatment center; and discusses the importance of clinical trial participation that takes into account the patient treatment goals, as well as identifying patient subgroups that may differentially benefit from certain types of therapies – ie, moving toward precision medicine in this disease.

Intended Audience

This activity is intended for oncologists and other health care providers who care for patients with pancreatic cancer.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Review the outcomes for different subsets of patients with pancreatic cancer
  • Identify patients who should be referred for management at a high-volume treatment center
  • Apply the NCCN guidelines to develop treatment plans
  • Develop a personal policy for discussing clinical trial participation with patients that takes into account the low enrollment into trials, the need for trial participation, and patient treatment goals

Conflict Of Interest Disclosure Policy

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Eileen M. O’Reilly, MD
Section Head Hepatopancreaticobiliary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. O’Reilly discloses the following:
Research Support: ActaBiologica, Agios, Array, AstraZeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris, Puma, QED, Roche
Consultant: 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla,CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Genoscience, Gilead, Halozyme, Hengrui, Inovio, Ipsen, Jazz, Jansen, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Newlink Genetics, Novella, Onxeo, PCI Biotech, Pfizer, Pharmacyte, Pharmacyclics, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vicus, Yakult, Yiviva

Publishing Staff Disclosures

The staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Additional content planners
Constantin A. Dasanu, MD, PhD (peer reviewer) has no significant relationship to disclose.
Emir Hadzik, PhD (medical writer) has no significant relationship to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The faculty for this activity has disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Instructions

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications for your practice, and completing the assessment component.

Please note: The content of this activity is housed on the website of our educational partner, Annenberg Center for Health Sciences at Eisenhower, and requires you to leave myCME and register on the Annenberg website.

Your certificate will be saved on the Annenberg website only and cannot be accessed in your myCME CME History. Please go to https://education.annenberg.net and sign in to access your certificate in the future.

Contact Information

For help or questions about this Internet activity, please contact Annenberg Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Privacy Policy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

myCME privacy policy
Add to Queue